Systemic Therapy Options for Uveitis

Drs. Jessica Shantha and Brian Do discuss systemic therapy options for uveitis including corticosteroids and steroid-sparing options, with guidance from major trial results.

CME Information

Release: July 15, 2022; expires July 15, 2025

Disclosures: 
Planner/Faculty: Dr. Sridhar reports no relevant financial disclosures.
Faculty: Drs. Do and Shantha report no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards in the management of uveitis and the outcomes from recent research and how these impact patient care decisions.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.